GSK’s Arranon Response Rates Likely To Predict Clinical Benefit In Leukemia/Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drug Products Advisory Committee votes for accelerated approval of Arranon for relapsed T-cell leukemia and lymphoma.